Our latest
News
Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure
Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure
Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025
Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification
Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation
Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025
Publication of the 2024 Annual Financial Report
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications
Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update
Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player
Mauna Kea Technologies announces the opening of a safeguard proceeding to restructure its financial liabilities
No results found.